• 대한두경부종양학회:학술대회논문집
• /
• 1999.12a
• /
• pp.281-284
• /
• 1999

• 대한위암학회:학술대회논문집
• /
• 2003.11a
• /
• pp.59-59
• /
• 2003

• 대한위암학회:학술대회논문집
• /
• 2003.11a
• /
• pp.25-27
• /
• 2003

• Tuberculosis and Respiratory Diseases
• /
• v.58 no.5
• /
• pp.465-472
• /
• 2005

Background : The survival benefit associated with first-line chemotherapy in lung cancer has led to the need for second-line chemotherapy, for which Docetaxel ($Taxotere^{(R)}$) has proven efficacy in both settings. This study evaluated the safety and efficacy of docetaxel in patients with non-small cell lung cancer who had failed first-line platinum-based chemotherapy. Methods : Thirty one patients with non-small-cell lung cancer, who had failed first-line platinum-based chemotherapy, between March 1999 and August 2003, were enrolled in this study. Patients received intravenous docetaxel, either $75mg/m^2$ or $100mg/m^2$, with routine premedication every three weeks. Results : Fourteen patients (45.2%) had a partial response. The median survival and progression-free survival times were 12.5 months (95% CI 7.3-17.6) and 3.0 months (95% CI 1.6-4.5), respectively. This study showed 2 factors gave different survival benefits; the age (< 60 years: 20.1 months vs. ${\geq}60years$: 6.6 months, p = 0.0105) and the histological type (adenocarcinoma: 25.6 months vs. others: 7.9 months, p=0.0055). The predominant toxicity was neutropenia, which occurred as WHO grade 3 or 4 in 38.7 % of patients. One treatment-related death was also reported. Non-hematological toxicity was minor and easily controlled. There were no significant statistical differences in the survival benefit and toxicity between the two doses. Conclusion : Docetaxel, as second-line monotherapy, was well tolerated and effective in patients with non-small-cell lung cancer who failed first-line platinum-based chemotherapy.

• Radiation Oncology Journal
• /
• v.27 no.2
• /
• pp.71-77
• /
• 2009

Purpose: We investigated the outcome and the prognostic factors of patients with locally advanced esophageal cancer who were treated with concurrent chemo-radiotherapy. Materials and Methods: Two hundred forty six patients with esophageal cancer that were treated by radiotherapy between January 1994 and July 2007. Of these, 78 patients who received radiotherapy of $\geq$45 Gy with concurrent chemotherapy were retrospectively enrolled in this study. We included patients stages IIA, IIB, III, IVA, and IVB with supraclavicular metastasis in the middle/lower esophageal cancer or celiac node metastasis in cervical or upper/middle thoracic esophageal cancer. The median radiation dose was 54 Gy and the combination chemotherapy with 5-FU and cisplatin (FP chemotherapy) was given concurrently with radiotherapy in most patients (88%). Results: The follow-up period ranged from 2 to 117 months (median 14 months). The treatment response of the 54 patients could be evaluated by computerized tomography or endoscopy. A complete response (CR) was observed in 17 patients, whereas a partial response was observed in 18 patients. In patients with a CR, the median recurrence time was 20 months and the first relapse sites constituted a locoregional failure in 3 patients and a distant failure in 7 patients. The 1-, 2-, and 5-year overall survival (OS) rates were 58.9%, 21.7%, and 12.2%, respectively. The median survival period was 14 months. A univariate analysis indicated that the treatment response and cycles of FP chemotherapy were significant prognostic factors for OS. Daily or weekly administration of cisplatin as a radiosensitizer showed a better treatment response than FP chemotherapy. Conclusion: This study has shown that results of concurrent chemo-radiotherapy in patients with locally advanced esophageal cancer is comparable to those of other studies. Daily or weekly cisplatin administration may be considered as an alternative treatment in patients that are medically unfit for FP chemotherapy.

• Korean Journal of Adult Nursing
• /
• v.19 no.5
• /
• pp.115-126
• /
• 2007

Purpose: The present study is a quasi-experimental research for examining the effects of imagery on stress, anxiety and immune cells in acute leukemia patients receiving chemotherapy and utilizing the therapy for their self control and stress management. Methods: The subjects were 60 patients who were diagnosed with acute leukemia and scheduled to receive chemotherapy at A hospital in Seoul during the period from November 2006 to March 2007. After the start of chemotherapy, the experimental group received imagery for 4 weeks, three sessions a week, so a total of 12 sessions and 156 minutes. Results: The decrease of stress was larger in the experimental group than in the control group. Systolic blood pressure decreased significantly more in the experimental group than in the control group. In the experimental group, state anxiety decreased significantly in the 2nd week of the experiment and after the final stage of the experiment. The total number of white blood cells, and the absolute number of neutrophils and lymphocytes were showing significant differences between the time points. Conclusion: Imagery is an effective intervention for reducing stress and state anxiety and stabilizing blood pressure in acute leukemia patients receiving chemotherapy.

• Journal of Korean Academy of Nursing
• /
• v.17 no.3
• /
• pp.195-203
• /
• 1987

Twenty five cancer patients were assigned to two groups: The experimental group which received Progressive Muscle Relaxation (PMR) training and the control group without the training. Base line data for dependent variables -nausea and vomiting, state anxiety and symptom distress- were collected when the subjects of both groups received the first cycle chemotherapy. Then the experimental group was trained for PMR between the first and the second cycle chemotherapy. The same dependent variables were measured during the second cycle chemotherapy from the subjects. Results indicated that the PMR group showed no significant difference in severity of nausea and vomiting compared to the control group. Although the significance was not supported, the severity of nausea and vomiting in experimental group decreased while control group increased between the first and fifth day of the second cycle chemotherapy. The experimental group showed significantly less state anxiety during the second cycle than the control group (p＜0.01). Significantly low symptom distress was also reported in the experimental group compared to the control group(p<0.01). The result suggests that PMR training may be an effective procedure for helping cancer patients cope with the adverse effects of their chemotherapy.

• Journal of Home Health Care Nursing
• /
• v.24 no.2
• /
• pp.189-199
• /
• 2017

Purpose: This study aimed to investigate the effects of foot bath therapy on the symptom intensity, distress, and interference with usual activities due to chemotherapy-induced peripheral neuropathy (CIPN) in patients with metastatic and recurrent cancer. Methods: Foot bath therapy was administered to the experimental group for >8 sessions in 2 weeks, and the chemotherapy-induced peripheral neuropathy assessment tool (CIPNAT) was used to measure its effects on the symptom intensity, distress, and interference with usual activities due to CIPN. SPSS was used to perform data analyses including descriptive statistics, chi-square test, Fisher's exact test, t-test, paired t-test, and repeated measures ANCOVA. Results: A statistically significant difference in the variation of the symptom intensity, distress, and interference with usual activities due to CIPN was observed between the two groups; however, a statistically insignificant difference was observed between the groups and time of interaction. Conclusion: Foot bath therapy can be used as a simple and effective clinical or home care nursing intervention to improve the symptom intensity, distress and interference with usual activities due to CIPN.

• Journal of Gastric Cancer
• /
• v.7 no.3
• /
• pp.160-166
• /
• 2007

Purpose: Recently, chemosensitivity tests have become widely used for the selection of effective drugs in gastric cancer patients. In this study, a chemosensitivity test was performed to select agents to increase the effectiveness of adjuvant chemotherapy. Materials and Methods: Chemosensitivity testing was performed in 81 gastric cancer patients that received a gastrectomy at the Yeungnam University Hospital. An ATP (adenosine triphosphate) based chemotherapy response assay was used. Clinicopatholgical factors such as sex, age, expression of tumor markers (CEA and CA19-9 levels), location of the tumor, morphology of advanced cancer, histological type, cell differentiation, depth of invasion, Lauren classification, Ming classification, lymphatic invasion, vascular invasion, neural invasion, lymph node metastasis and TNM stage were used to correlate the chemosensitivity and clinicopathological factors. Results: The most effective antitumor agents in gastric cancer patients were (in order of effectiveness) 5-FU, Epirubicin, lrinotecan and Oxaliplatin in our series. The chemosensitivity test showed a significant difference in susceptibility according to clinicopathological factors. Conclusion: Further studies on multidrug therapy are needed to evaluate synergistic effects of drugs. Therefore, for effective chemotherapy, it is more efficacious to select a chemosensitive drug than continue to use the same drug regimen.

• Journal of Gastric Cancer
• /
• v.6 no.3
• /
• pp.139-145
• /
• 2006

Purpose: Although several chemotherapy regimens used against advanced gastric cancer (AGC) have been studied extensively in an attempt to further improve the prognosis of patients, to date, no standard chemo-therapeutic regimens have been established. The aim of this study was to determine the anti-tumor efficacy and safety of TS-1 or TS-1 plus cisplatin (CDDP). Material and Methods: We treated 78 patients with AGC either with $80\;mg/m^{2}$ of TS-1 for 28 days, which was followed by a 2-week rest, or with $80\;mg/m^{2}$ of TS-1 for 21 days and $80\;mg/m^{2}$ of CDDP on day 8 every 5 weeks. Results: Tumor response rates in the neoadjuvant chemotherapy group and in the recurrent or post-palliative surgery group were 87.5% and 32.4%, respectively, and they were 28.6% and 48.4%, respectively, in the TS-1 group and the TS-1 plus CDDP group. The survival rates in the recurrent and the post-palliative surgery group were significantly different according to the degree of tumor response (P=0.0016), but the one-year survival rates according to the kinds of regimens (TS-1 or TS-1/CDDP group) were not significantly different. The incidences of grade 3 or 4 adverse effects in the TS-1 and the TS-1/CDDP groups were 14.3% and 36.8%, respectively. Conclusion: The anti-tumor efficacy and safety of TS-1 and TS-1 plus CDDP in Korean patients with AGC seemed to be high with modest adverse effects, thus suggesting the possible use of this regimen as a standard chemotherapy for gastric cancer.